Results 121 to 130 of about 489,898 (256)

Comparative serological assays for the study of H5 and H7 avian influenza viruses. [PDF]

, 2013
The nature of influenza virus to randomly mutate and evolve into new types is an important challenge in the control of influenza infection. It is necessary to monitor virus evolution for a better understanding of the pandemic risk posed by certain ...
Temperton, Nigel J., Cattoli, Giovanni, Milani, Adelaide, Molesti, Eleonora, Terragino, Calogero   +4 more
core  

The need for novel influenza vaccines in low- and middle-income countries: A narrative review

Brazilian Journal of Infectious Diseases
Influenza viruses cause 3–5 million severe cases and 300,000–600,000 deaths worldwide. Most of the disease burden is in Low- and Middle-Income Countries (LMICs) owing to factors such as high population density, infrastructure challenges, poor quality ...
Julia R. Spinardi, Karan B. Thakkar, Verna L. Welch, Oladayo Jagun, Moe H. Kyaw   +4 more
doaj   +1 more source

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

Clinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert   +8 more
wiley   +1 more source

Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real‐World Data: The INVESTED‐Medicare Linkage Study

Clinical Pharmacology &Therapeutics, EarlyView.
Real‐world evidence (RWE) derived from real‐world data (RWD) can complement randomized controlled trials (RCTs), yet the validity of RWD relative to RCT data remains insufficiently characterized. We obtained post hoc consent and linked individual participant data from the US‐based INVESTED trial (2016–2019) with Medicare fee‐for‐service claims (2012 ...
Hanseul Cho, HoJin Shin, Mehdi Najafzadeh, Brian Claggett, Janinne Ortega‐Montiel, Jun Liu, Julie M. Paik, Narlina F. Lalani, Marie C. Bradley, John Concato, Scott D. Solomon, Orly Vardeny, Elisabetta Patorno   +12 more
wiley   +1 more source

Cross‐protective effect of a multicomponent fusion protein vaccine during a natural episode of Streptococcus zooepidemicus respiratory disease in ponies

Equine Veterinary Journal, EarlyView.
Abstract Background Streptococcus equi subspecies zooepidemicus is a highly diverse opportunistic pathogen of horses, associated with respiratory disease and endometritis. Objectives To characterise S. zooepidemicus isolates recovered from young ponies during a natural episode of respiratory disease, and to determine if vaccination with Strangvac®, a ...
Romain Paillot, J. Richard Newton, Sonia Gonzalez Medina, Sara Frosth, Lars Frykberg, Margareta Flock, Bengt Guss, Jan‐Ingmar Flock, Andrew S. Waller   +8 more
wiley   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Antibody kinetics against tetanus toxoid before and after primary vaccination of foals

Equine Veterinary Journal, EarlyView.
Abstract Background Vaccination recommendations for foals against Clostridium tetani vary. Available studies assessing foal immune responses, maternal antibody interference, or individual variation often used small foal numbers. Objectives To quantify antibody responses after tetanus vaccination in foals and explore associations with passively ...
Katharina Olbrich, Monica Venner, Bettina Wagner   +2 more
wiley   +1 more source

Genetic variants of EcPV2 E6 and E7 in equine genital and oronasal squamous cell carcinoma

Equine Veterinary Journal, EarlyView.
Abstract Background Since its discovery in 2008, equine papillomavirus type 2 (EcPV2) has been detected in up to 100% of equine genital and up to 40% of equine oronasal squamous cell carcinomas (SCCs). Preliminary sequence data point to the existence of EcPV2 E6 and E7 oncogene variants compared to the British reference sequence from 2008.
Maya Jenner, Sabine Brandt
wiley   +1 more source

Engineering mRNA‐LNP Medicines for the Ageing Brain: Opportunities and Challenges for Neurodegenerative Diseases

Exploration, EarlyView.
This review highlights recent advances in engineering messenger RNA (mRNA)‐lipid nanoparticles (LNPs) to cross the ageing blood–brain barrier and target neurodegenerative diseases. It outlines design principles, delivery routes, and translational challenges, charting a roadmap towards clinical application of mRNA‐LNP therapeutics for neurodegenerative ...
Abdel Ali Belaidi, Denzil L. Furtado, Francesca Alves, Rebecca M. Nisbet, Scott Ayton, Ashley I. Bush   +5 more
wiley   +1 more source

Influenza Virus: Global Health Impact, Strategies, Challenges, Role of Nanotechnolgy in Influenza Vaccine Development

Influenza is a serious and global health issue, and it is a major cause of morbidity, fatality, and economic loss every year. Seasonal vaccines exist but are not very effective due to strain mismatches, delays in production, and antigenic drift.
Ganesh Yadagiri, Anushree Pathrathota, Arjun L. Uppar, Shyam Lal Mudavath, Shabi Parvez   +4 more
core   +1 more source